36,215 Shares in Danaher Co. (NYSE:DHR) Acquired by Triavera Capital LLC

Triavera Capital LLC purchased a new position in shares of Danaher Co. (NYSE:DHR) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 36,215 shares of the conglomerate’s stock, valued at approximately $8,313,000. Danaher comprises about 4.5% of Triavera Capital LLC’s holdings, making the stock its 12th largest holding.

A number of other institutional investors and hedge funds have also modified their holdings of DHR. Norges Bank bought a new stake in shares of Danaher during the fourth quarter worth approximately $2,130,740,000. Raymond James Financial Inc. bought a new stake in shares of Danaher during the fourth quarter worth approximately $391,172,000. Capital World Investors grew its holdings in Danaher by 32.7% during the fourth quarter. Capital World Investors now owns 6,361,183 shares of the conglomerate’s stock valued at $1,460,215,000 after purchasing an additional 1,566,658 shares during the period. Point72 Asset Management L.P. grew its holdings in Danaher by 460.6% during the fourth quarter. Point72 Asset Management L.P. now owns 1,348,544 shares of the conglomerate’s stock valued at $309,558,000 after purchasing an additional 1,107,998 shares during the period. Finally, Northern Trust Corp grew its holdings in Danaher by 14.3% during the fourth quarter. Northern Trust Corp now owns 7,934,991 shares of the conglomerate’s stock valued at $1,821,477,000 after purchasing an additional 992,594 shares during the period. 79.05% of the stock is owned by institutional investors.

Danaher Stock Up 2.7%

Shares of DHR stock opened at $196.03 on Friday. The firm has a fifty day moving average of $196.87 and a 200-day moving average of $217.47. The company has a quick ratio of 1.05, a current ratio of 1.40 and a debt-to-equity ratio of 0.31. The company has a market capitalization of $140.29 billion, a price-to-earnings ratio of 37.13, a P/E/G ratio of 2.66 and a beta of 0.80. Danaher Co. has a 12-month low of $171.00 and a 12-month high of $281.70.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Tuesday, April 22nd. The conglomerate reported $1.88 EPS for the quarter, topping analysts’ consensus estimates of $1.62 by $0.26. The business had revenue of $5.74 billion for the quarter, compared to analyst estimates of $5.58 billion. Danaher had a net margin of 16.33% and a return on equity of 10.82%. As a group, equities research analysts predict that Danaher Co. will post 7.63 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, July 25th. Stockholders of record on Friday, June 27th will be given a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.65%. Danaher’s dividend payout ratio is presently 24.85%.

Insider Transactions at Danaher

In other Danaher news, Chairman Steven M. Rales sold 1,250,000 shares of the company’s stock in a transaction on Monday, May 12th. The shares were sold at an average price of $196.74, for a total transaction of $245,925,000.00. Following the sale, the chairman now directly owns 3,105,808 shares of the company’s stock, valued at approximately $611,036,665.92. This represents a 28.70% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Christopher Paul Riley sold 15,805 shares of the company’s stock in a transaction on Wednesday, April 30th. The stock was sold at an average price of $198.00, for a total transaction of $3,129,390.00. Following the sale, the executive vice president now directly owns 15,179 shares in the company, valued at $3,005,442. This trade represents a 51.01% decrease in their ownership of the stock. The disclosure for this sale can be found here. 11.10% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

DHR has been the subject of a number of analyst reports. UBS Group decreased their price objective on shares of Danaher from $275.00 to $240.00 and set a “buy” rating for the company in a report on Wednesday, April 23rd. StockNews.com upgraded shares of Danaher from a “hold” rating to a “buy” rating in a report on Monday, May 12th. Citigroup restated a “buy” rating on shares of Danaher in a report on Monday, April 7th. Stifel Nicolaus upgraded shares of Danaher from a “hold” rating to a “buy” rating and set a $260.00 price objective for the company in a report on Friday, March 14th. Finally, Wells Fargo & Company decreased their price objective on shares of Danaher from $280.00 to $240.00 and set an “equal weight” rating for the company in a report on Thursday, January 30th. Four analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $264.40.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.